Skip to content

Mannkind MNKD Proceeds From Sale Of Future Royalties

Proceeds From Sale Of Future Royalties at other companies

Xencor logo
XencorXNCR
$0
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$0
uniQure logo
uniQureQURE
$92.52M
Geron logo
GeronGERN
$0-100%
Nuvation Bio logo
Nuvation BioNUVB
$864K
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$0-100%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:ProceedsFromSaleOfFutureRoyalties.

The official record: Mannkind’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's proceeds from sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's proceeds from sale of future royalties?
Mannkind (MNKD) reported proceeds from sale of future royalties of $37.5M in Q4 2023.
What does proceeds from sale of future royalties mean?
This represents cash received upfront in exchange for the right to a portion of future royalty revenue streams from products or intellectual property. It is a form of non-dilutive financing used to generate immediate liquidity by monetizing long-term revenue assets.